Stay always up-to-datewith our corporate news
Company has strengthened and enhanced its market position in the fast-growing US needle business.
Ypsomed investing in Switzerland.
At the general meeting of 27 June 2012 Ypsomed shareholders approved the growth strategy.
Ypsomed has recruited two experienced diabetes care executives to boost its diabetes treatment product franchise.
In the past 2011/12 business year, the Ypsomed Group increased net profit by 55.5% to CHF 8.5 million, which was positively affected by the sale of financial assets.
Ypsomed is expanding its mylife product range with the innovative self-injection system mylife DailyDose.